GUARDANT HEALTH INC (GH)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for GH
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GH | Director; Former President, Chief Executive Officer and Chairperson of Sumitomo Pharma America, Inc. | 67 | ["Experience in the biotechnology industry","Extensive commercial and operational experience leading pharmaceutical companies","Experience serving on boards of public companies"] | ["Audit Committee","Compensation Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AXSM | Chief Executive Officer | 61 | ["Chief Executive Officer of Sumitovant Biophama, Inc.","Vant Operating Chair of Roivant Sciences","Founder of Myrtle Potter & Company LLC","Former COO and President of Commercial Operations of Genentech, Inc.","Former President of Bristol-Myers Squibb’s U.S. Cardiovascular and Metabolic business","Experience at Merck, founded Astra/Merck"] | [] | 2020 |
| INSM | Director | 59 | ["CEO of Myrtle Potter & Company, LLC (2005 - present)", "Director at Express Scripts (2012)", "Director at Everyday Health (2010 - 2016)", "Director at Medco Health Solutions (2007 - 2012)", "President of Commercial Operations at Genentech (2000 - 2005)", "Vice President at Merck & Co., Inc. (1982 - 1996)", "Director at Rite Aid (NYSE: RAD)", "Director at Axsome Therapeutics, Inc. (NYSE: AXSM)", "Director at Liberty Mutual Holding Company", "Director at Proteus Digital Health", "Trustee at The University of Chicago", "B.A. in political science from University of Chicago", "Over 35 years of experience in the pharmaceutical industry"] | ["Compensation Committee"] | 2018 |
Biography sourced from the proxy statement filing.
Myrtle Potter has served as a member of our Board since October 2021. Ms. Potter most recently served as President, Chief Executive Officer and Chairperson of the Board of Sumitomo Pharma America, Inc. from July 1, 2023 to April 1, 2024. Prior to this, Ms. Potter served as the Chief Executive Officer of Sumitovant Biopharma, Inc., a subsidiary of Sumitovant Biopharma Ltd., from December 2019 to July 2023, when Sumitomo Pharma America, Inc. announced its launch resulting from the combination of Sumitovant and its wholly owned U.S. subsidiaries and other U.S. Sumitomo Pharma wholly owned subsidiaries. Previously, from 2018 to 2019, Ms. Potter served as Vant Operating Chair at Roivant Sciences, Ltd., and as Chief Executive Officer of Myrtle Potter & Company, LLC from 2005 to 2018. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to joining Genentech, she held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb, and a vice president at Merck & Co. Ms. Potter currently serves on the Board of Directors of Opentrons Labworks, Inc. Ms. Potter previously served on the Board of Directors of Liberty Mutual Holding Company, Inc. from April 2013 to April 2026, Ginkgo Bioworks Holdings, Inc. from June 2024 to June 2025, Myovant Sciences, Ltd. from September 2018 to March 2023, Urovant Sciences Ltd. from July 2018 to March 2021, Axsome Therapeutics, Inc. from June 2017 to June 2020, Everyday Health, Inc. from September 2010 to December 2016, Immunovant, Inc. from June 2019 to February 2020, Axovant Gene Therapies, Ltd. from September 2018 to February 2020, Arbutus Biopharma, Inc. from October 2018 to February 2020, Insmed Incorporated from December 2014 to November 2018, and Rite Aid Corporation from November 2013 to September 2018. Ms. Potter holds a Bachelor of Arts Degree from The University of Chicago. We believe that Ms. Potter is qualified to serve as a member of our Board due to her years of experience in the biotechnology industry, including extensive commercial and operational experience leading pharmaceutical companies in bringing new therapies to market and her extensive experience serving on boards of public companies.